The weekly litigation news digest is live. Subscribe now

IP Verse

ToolGen, Inc. v. Vertex Pharmaceuticals, Inc. - 1:25-cv-13441

ToolGen, Inc. v. Vertex Pharmaceuticals, Inc. (Case No. 1:25-cv-13441), filed on Nov 18, 2025 in the District Court, D. Massachusetts involving patent infringement. This case involves patent infringement claims between the parties. Explore details about the litigants, key filings, and major docket updates.

Case Details

Case Number
1:25-cv-13441
Filing Date
Nov 18, 2025
Cause of Action
Patent Infringement
Status
-
Court
District Court, D. Massachusetts
Nature of Suit
Patent

Parties Involved

The following parties are involved in this case, with their respective legal representatives for the case.

NameRepresented By
Biomay AG -
Vertex Pharmaceuticals (Ireland), Limited -
CRISPR Therapeutics AG -
ToolGen, Inc. -
Roslin Cell Therapies Limited -
RoslinCT US Holdings, LLC -
Lonza Netherlands B.V. -
Charles River Laboratories Inc. -

Patents Involved

There is a single patent involved in this case.

Application NumberPatent Number
-US12473559B2

Docket Entries

The Docket Entries section provides a chronological list of all significant filings and court actions in this case.

DateDocket EntryType

Set alerts for critical docket entry

Nov 18, 2025Summons Issued as to Biomay AG, CRISPR Therapeutics AG, CRISPR Therapeutics Inc., Charles River Laboratories Inc., Lonza Group AG, Lonza Netherlands B.V., Roslin Cell Therapies Limited, RoslinCT US Holdings, LLC, Vertex Pharmaceuticals (Canada), Incorporated, Vertex Pharmaceuticals (Europe), Limited, Vertex Pharmaceuticals (Ireland), Limited, Vertex Pharmaceuticals, Inc.. Counsel receiving this notice electronically should download this summons, complete one for each defendant and serve it in accordance with Fed.R.Civ.P. 4 and LR 4.1. Summons will be mailed to plaintiff(s) not receiving notice electronically for completion of service. (SP) (Entered: 11/18/2025)PACER Document
Nov 18, 2025CORPORATE DISCLOSURE STATEMENT by ToolGen, Inc.. (Stern, Benjamin) (Entered: 11/18/2025)PACER Document
Nov 18, 2025REPORT ON THE FILING OF AN ACTION REGARDING PATENT OR TRADEMARK. (Stern, Benjamin) (Entered: 11/18/2025)PACER Document
Nov 18, 2025COMPLAINT against CRISPR Therapeutics AG, RoslinCT US Holdings, LLC, Vertex Pharmaceuticals (Canada), Incorporated, CRISPR Therapeutics Inc., Lonza Netherlands B.V., Vertex Pharmaceuticals, Inc., Charles River Laboratories Inc., Lonza Group AG, Vertex Pharmaceuticals (Europe), Limited, Biomay AG, Roslin Cell Therapies Limited, Vertex Pharmaceuticals (Ireland), Limited Filing fee: $ 405, receipt number AMADC-11365746 (Fee Status: Filing Fee paid), filed by ToolGen, Inc.. (Attachments: # 1 Exhibit 1 (US Patent 12,473,559 B2), # 2 Civil Cover Sheet, # 3 Category Form)(Stern, Benjamin) (Entered: 11/18/2025)PACER Document
Nov 18, 2025NOTICE of Case Assignment. Magistrate Judge M. Page Kelley assigned to case. Plaintiff's counsel, or defendant's counsel if this case was initiated by the filing of a Notice of Removal, are required to submit a form indicating whether the parties consent to proceed before a U.S. Magistrate Judge. The submission of the form is mandatory. Completed forms shall be filed promptly. The parties are directed to the Notice and Procedures regarding Consent to Proceed before the Magistrate Judge which can be downloaded here. These documents will be mailed to counsel not receiving notice electronically. Pursuant to General Order 09-3, until the Court receives for filing either a consent to the Magistrate Judge's jurisdiction or the reassignment of the case to a District Judge, the initial assignment of a civil case to the Magistrate Judge is a referral to the Magistrate Judge under 28 USC 636(b) for all pretrial non-dispositive matters and Report and Recommendations, but not for the Rule 16(b) scheduling conference. (SP) (Entered: 11/18/2025)PACER Document
Nov 18, 2025COMPLAINT against CRISPR Therapeutics AG, RoslinCT US Holdings, LLC, Vertex Pharmaceuticals (Canada), Incorporated, CRISPR Therapeutics Inc., Lonza Netherlands B.V., Vertex Pharmaceuticals, Inc., Charles River Laboratories Inc., Lonza Group AG, Vertex Pharmaceuticals (Europe), Limited, Biomay AG, Roslin Cell Therapies Limited, Vertex Pharmaceuticals (Ireland), Limited Filing fee: $ 405, receipt number AMADC-11365746 (Fee Status: Filing Fee paid), filed by ToolGen, Inc.. (Attachments: # 1 Exhibit 1 (US Patent 12,473,559 B2), # 2 Civil Cover Sheet, # 3 Category Form)(Stern, Benjamin) (Entered: 11/18/2025)Attachment
Nov 18, 2025COMPLAINT against CRISPR Therapeutics AG, RoslinCT US Holdings, LLC, Vertex Pharmaceuticals (Canada), Incorporated, CRISPR Therapeutics Inc., Lonza Netherlands B.V., Vertex Pharmaceuticals, Inc., Charles River Laboratories Inc., Lonza Group AG, Vertex Pharmaceuticals (Europe), Limited, Biomay AG, Roslin Cell Therapies Limited, Vertex Pharmaceuticals (Ireland), Limited Filing fee: $ 405, receipt number AMADC-11365746 (Fee Status: Filing Fee paid), filed by ToolGen, Inc.. (Attachments: # 1 Exhibit 1 (US Patent 12,473,559 B2), # 2 Civil Cover Sheet, # 3 Category Form)(Stern, Benjamin) (Entered: 11/18/2025)Attachment
Nov 18, 2025COMPLAINT against CRISPR Therapeutics AG, RoslinCT US Holdings, LLC, Vertex Pharmaceuticals (Canada), Incorporated, CRISPR Therapeutics Inc., Lonza Netherlands B.V., Vertex Pharmaceuticals, Inc., Charles River Laboratories Inc., Lonza Group AG, Vertex Pharmaceuticals (Europe), Limited, Biomay AG, Roslin Cell Therapies Limited, Vertex Pharmaceuticals (Ireland), Limited Filing fee: $ 405, receipt number AMADC-11365746 (Fee Status: Filing Fee paid), filed by ToolGen, Inc.. (Attachments: # 1 Exhibit 1 (US Patent 12,473,559 B2), # 2 Civil Cover Sheet, # 3 Category Form)(Stern, Benjamin) (Entered: 11/18/2025)Attachment